美洲 · 区域市场 · Financial Post
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancer…
在 Financial Post 阅读全文 登录后可收藏MarketNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (financialpost.com)
